KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.

Christopher C Butler, Andrew D Pinto, Victoria Harris, Jane Holmes, Najib M Rahman, Lucy Cureton, Gail Hayward, Duncan B Richards, David M Lowe, Joseph F Standing, Judith Breuer, Kerenza Hood, May Ee Png, Stavros Petrou, Jienchi Dorward, Mahendra G Patel, Nicholas P B Thomas, Philip Evans, Nigel D Hart, Bhautesh D Jani, Banafshe Hosseini, Srinivas Murthy, Kerry McBrien, Amanda Condon, Emily G McDonald, Peter Daley, Michelle Greiver, Bruno R da Costa, Peter Selby, Peter Jüni, Todd C Lee, Haolun Shi, Michelle A Detry, Christina T Saunders, Mark Fitzgerald, Nicholas S Berry, Benjamin R Saville, Saye H Khoo, Jonathan S Nguyen-Van-Tam, F D Richard Hobbs, Ly-Mee Yu, Paul Little, PANORAMIC Trial and CanTreatCOVID Trial Collaborative Groups

N Engl J Med 394(16) 1583-1594

PMID42019019
PMCIDPMC7619176
DOI10.1056/NEJMoa2502457
发表日期2026-04-22
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:A:图注未提示 KM 曲线;B:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: Nirmatrelvir-ritonavir has been shown to reduce progression to severe illness from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in unvaccinated high-risk outpatients. The effectiveness of nirmatrelvir-ritonavir in persons who have been vaccinated, infected naturally, or both is unclear. METHODS: In two open-label platform trials (PANORAMIC in the United Kingdom and CanTreatCOVID in Canada), we enrolled higher-risk adults (≥50 years of age or ≥18 years of age with coexisting conditions) in the community who tested positive for SARS-CoV-2 and had been unwell for 5 days or less. The participants were randomly assigned to receive usual care plus nirmatrelvir (300 mg)-ritonavir (100 mg) twice a day for 5 days or to receive usual care alone. The primary outcome was hospitalization or death from any cause within 28 days after randomization. RESULTS: From December 8, 2021, to September 30, 2024, a total of 3516 participants in the PANORAMIC trial and 716 participants in the CanTreatCOVID trial underwent randomization. In the PANORAMIC trial, 14 of 1698 participants (0.8%) in the nirmatrelvir-ritonavir group and 11 of 1673 participants (0.7%) in the usual-care group were hospitalized or died (adjusted odds ratio, 1.18; 95% Bayesian credible interval, 0.55 to 2.62; probability of superiority, 0.334). In the CanTreatCOVID trial, 2 of 343 participants (0.6%) in the nirmatrelvir-ritonavir group and 4 of 324 participants (1.2%) in the usual-care group were hospitalized or died (adjusted odds ratio, 0.48; 95% Bayesian credible interval, 0.08 to 2.23; probability of superiority, 0.830). In a substudy involving 634 participants, viral load was reduced by the end of treatment with nirmatrelvir-ritonavir. Serious adverse events with nirmatrelvir-ritonavir were reported in 9 participants in the PANORAMIC trial and in 4 participants in the CanTreatCOVID trial. CONCLUSIONS: In two open-label trials, nirmatrelvir-ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection. (Funded by the National Institute for Health and Care Research, and others; PANORAMIC ISRCTN number, 2021-005748-31; CanTreatCOVID ClinicalTrials.gov number, NCT05614349.).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

A无图注
非 KM Figure
B无图注
非 KM Figure